- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02704325
Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2
February 2, 2018 updated by: Kevin Flanigan
Phase I Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2
The proposed clinical trial study of rAAVrh74.MCK.GALGT2 for duchenne muscular dystrophy (DMD) patients that will involve direct intramuscular injection to the extensor digitorum brevis muscle (EDB).
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
This is a phase I safety and tolerability study.
Three DMD subjects will receive bilateral injections into the EDB muscle, with one EDB receiving the GALGT2 vector (rAAVrh74.MCK.GALGT2) and the other side receiving saline alone (assigned in a randomized fashion).
Three subjects will receive a single gene transfer dose of 1E12 vector genomes, and patients and investigators will be blinded as to which muscle is injected with vector.
Muscle biopsies will be performed at three months (12 weeks) in two subjects and at 1.5 months (6 weeks) in one subject and evaluated blindly for the expression of the GALGT2 transgene.
Study Type
Interventional
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43205
- Nationwide Children's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
7 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Nonambulant subjects, age 9 or older
- Confirmed mutation in the DMD gene using a clinically accepted technique that completely defines the mutation
- A magnetic resonance image of the EDB showing preservation of sufficient muscle mass to permit transfection
- Males of any ethnic group will be eligible
- Ability to cooperate with all study procedures
- Willingness of sexually active subjects with reproductive capacity to practice reliable method of contraception (If appropriate).
- Stable dose of corticosteroid therapy (including either prednisone or deflazacort and their generic forms) for 12 weeks prior to gene transfer
Exclusion Criteria:
- Active viral infection based on clinical observations.
- The presence of a DMD mutation without weakness or loss of function
- Symptoms or signs of cardiomyopathy, including:
- Dyspnea on exertion, pedal edema, shortness of breath upon lying flat, or rales at the base of the lungs
- Echocardiogram with ejection fraction below 40%
- Serological evidence of HIV infection, or Hepatitis A, B or C infection
- Diagnosis of (or ongoing treatment for) an autoimmune disease
- Persistent leukopenia or leukocytosis (WBC ≤ 3.5 K/µL or ≥ 20.0 K/µL) or an absolute neutrophil count < 1.5K/µL
- Concomitant illness or requirement for chronic drug treatment that in the opinion of the PI creates unnecessary risks for gene transfer
- Subjects with rAAVrh74 binding antibody titers ≥ 1:400 as determined by ELISA immunoassay
- Presence of circulating anti-Sda antibodies as determined by study approved laboratory.
- Abnormal laboratory values in the clinically significant range, based upon normal values in the Nationwide Children's Hospital Laboratory
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: GALGT2 Viral Vector
Dose: 1E12 vg (total dose) (n=3) of rAAVrh74.MCK.GALGT2 vs Placebo (Saline).
All participants will receive rAAVrh74.MCK.GALGT2 in the right or the left EDB muscle and receive Saline in the opposite EDB muscles.
The investigator will not know which side will receive rAAVrh74.MCK.GALGT2 vs Saline until after the trial is over.
At the end of the trial the investigator will be unblinded.
|
Direct intramuscular injection of rAAVrh74.MCK.GALGT2 transferred to the extensor digitorum brevis muscle (EDB) of one foot and the other side receiving saline alone.
|
Experimental: Saline
Dose: 1E12 vg (total dose) (n=3) of rAAVrh74.MCK.GALGT2 vs Placebo (Saline).
All participants will receive rAAVrh74.MCK.GALGT2 in the right or the left EDB muscle and receive Saline in the opposite EDB muscles.
The investigator will not know which side will receive rAAVrh74.MCK.GALGT2 vs Saline until after the trial is over.
At the end of the trial the investigator will be unblinded.
|
Direct intramuscular injection of rAAVrh74.MCK.GALGT2 transferred to the extensor digitorum brevis muscle (EDB) of one foot and the OTHER side receiving saline alone.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment related toxicities
Time Frame: 2 years
|
Based on the development of unacceptable toxicity defined as the occurrence of any one Grade III or higher treatment-related toxicities.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Expression of GALGT2 demonstrated with anti-CT epitope antibodies.
Time Frame: 6 or 12 weeks
|
6 or 12 weeks
|
GALGT2 protein expression quantified by western blot and assessed by densitometry
Time Frame: 6 or 12 weeks
|
6 or 12 weeks
|
Transduction efficiency measured by qPCR of the GALGT transgene from muscle, and expressed as vector genomes normalized to a genomic single-copy control.
Time Frame: 6 or 12 weeks
|
6 or 12 weeks
|
Number of fibers containing central nuclei compared between muscles by paired t-tests
Time Frame: 6 or 12 weeks
|
6 or 12 weeks
|
Dystrophin expression demonstrated with antibodies to N-terminal, C-terminal, and rod domains
Time Frame: 6 or 12 weeks
|
6 or 12 weeks
|
Utrophin expression
Time Frame: 6 or 12 weeks
|
6 or 12 weeks
|
Leukocyte markers including CD45, CD3, CD4, CD8, and MAC 387
Time Frame: 6 or 12 weeks
|
6 or 12 weeks
|
Muscle will be examined for histological appearance
Time Frame: 6 or 12 weeks
|
6 or 12 weeks
|
Antibodies to rAAVrh74 along with PBMC ELISpots to both rAAVrh74 capsid and GALGT protein will be evaluated at different time points during the study
Time Frame: 6 or 12 weeks
|
6 or 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Chicoine LG, Rodino-Klapac LR, Shao G, Xu R, Bremer WG, Camboni M, Golden B, Montgomery CL, Shontz K, Heller KN, Griffin DA, Lewis S, Coley BD, Walker CM, Clark KR, Sahenk Z, Mendell JR, Martin PT. Vascular delivery of rAAVrh74.MCK.GALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin alpha2 surrogates. Mol Ther. 2014 Apr;22(4):713-24. doi: 10.1038/mt.2013.246. Epub 2013 Oct 22.
- Martin PT, Xu R, Rodino-Klapac LR, Oglesbay E, Camboni M, Montgomery CL, Shontz K, Chicoine LG, Clark KR, Sahenk Z, Mendell JR, Janssen PM. Overexpression of Galgt2 in skeletal muscle prevents injury resulting from eccentric contractions in both mdx and wild-type mice. Am J Physiol Cell Physiol. 2009 Mar;296(3):C476-88. doi: 10.1152/ajpcell.00456.2008. Epub 2008 Dec 24.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
April 1, 2016
Primary Completion (Anticipated)
July 1, 2018
Study Completion (Anticipated)
February 1, 2020
Study Registration Dates
First Submitted
December 23, 2015
First Submitted That Met QC Criteria
March 4, 2016
First Posted (Estimate)
March 10, 2016
Study Record Updates
Last Update Posted (Actual)
February 6, 2018
Last Update Submitted That Met QC Criteria
February 2, 2018
Last Verified
February 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GALGT2 for DMD
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Duchenne Muscular Dystrophy
-
Cairo UniversityCompletedMuscular Dystrophy, Duchenne TypeEgypt
-
Medical University of GdanskRecruitingDuchenne Muscular Dystrophy (DMD)Poland
-
ItalfarmacoCompletedDuchenne Muscular Dystrophy (DMD)Italy
-
Santhera PharmaceuticalsTerminatedDuchenne Muscular Dystrophy (DMD)United States, Spain, Netherlands, Sweden, Germany, France, Belgium, United Kingdom, Italy, Ireland, Switzerland, Austria, Bulgaria, Hungary, Israel
-
Sarepta Therapeutics, Inc.CompletedDuchenne Muscular Dystrophy (DMD)United States
-
Hospital RudolfstiftungOesterreichische MuskelforschungCompletedCarrier of Duchenne Muscular DystrophyAustria
-
General Hospital of Chinese Armed Police ForcesUnknownDuchenne Muscular Dystrophy (DMD)China
-
Chaitanya Hospital, PuneUnknownMuscular Dystrophy | Duchenne Muscular Dystrophy,India
-
University of FloridaU.S. Army Medical Research and Development CommandRecruitingDuchenne Muscular Dystrophy (DMD)United States
-
PTC TherapeuticsCompletedNonsene Mutation Duchenne Muscular DystrophyUnited States
Clinical Trials on rAAVrh74.MCK.GALGT2
-
Kevin FlaniganActive, not recruitingDuchenne Muscular DystrophyUnited States
-
Jerry R. MendellEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedDuchenne Muscular DystrophyUnited States
-
Sarepta Therapeutics, Inc.Active, not recruiting
-
Sarepta Therapeutics, Inc.Completed